Paperonium

← Back to the plain-language case

Abstract reports all-grade adverse event rates as grade ≥3 treatment-related rates in a phase I trial

Clin Cancer Res (2025) · doi:10.1158/1078-0432.CCR-24-1983 · PMC12163594

Summary

The Abstract of this first-in-human phase I trial of intratumoral SAR441000, given alone or with cemiplimab, states that the most common grade ≥3 treatment-related adverse events (TRAEs) were fatigue in escalation (28.6% with monotherapy, 66.7% with the combination) and injection-site pain in expansion (31.7%). All three percentages equal the all-grade, all-causality treatment-emergent AE (TEAE) rates in Table 2B (6/21, 10/15 and 13/41). In the same table, grade ≥3 fatigue is 0/21 and 0/15, and grade ≥3 injection-site pain is 1/41 (2.4%). The paper's own Table 2A and Results text add that no monotherapy patient had a grade ≥3 TRAE of any kind and that only 1 of 15 escalation-combination patients did. Safety was a primary objective, and this sentence is the Abstract's only quantitative safety result. As printed, it overstates severe treatment-related toxicity by about 10-fold or more.

What the paper reports

The most common grade ≥3 treatment–related adverse events was fatigue in the escalation phase (monotherapy: 28.6% and combination therapy: 66.7%) and injection-site pain (31.7%) in the expansion phase.

— Abstract, Results

Of the 21 patients, 19 (90.5%) experienced any-grade AEs, of which the most common were vomiting and fatigue in 6 (28.6%) patients each, followed by hypertension, chills, and pain in extremities in 4 (19.0%) patients each. Nine (42.9%) patients experienced grade ≥3 AEs (Table 2). Furthermore, 13 (61.9%) patients reported TRAEs, but none were grade ≥3 or considered serious; grade ≥5 AEs were not reported.

— Results, Safety, "Escalation monotherapy"

All 15 patients experienced any-grade AEs, with the most common being fatigue (10/15; 66.7%), followed by hypertension and nausea in 5 (33.3%) patients each. Grade ≥3 AEs—hypertension, pyrexia, and anemia—were experienced by one (6.7%) patient each (Table 2). Ten (66.7%) patients experienced any-grade TRAEs, with the most common being fatigue (n = 7; 46.7%). One (6.7%) patient experienced grade ≥3 syncope (Supplementary Table S5).

— Results, Safety, "Escalation combination therapy"

All 41 patients experienced any-grade AEs, of which injection-site pain (n = 13; 31.7%) was the most common all-grade AE, followed by diarrhea, decreased appetite, and asthenia (n = 11 each; 26.8%; Table 2). [...] Thirty-three (80.5%) patients had any-grade TRAEs, of which six (14.6%) patients had TRAEs of grade ≥3 that were diarrhea, injection-site pain, and fatigue (Supplementary Table S5).

— Results, Safety, "Expansion combination"

Patients with any TRAE of grade ≥3 | 0 | 1 (6.7) | 6 (14.6)

— Table 2A ("AEs: (A) summary and (B) TEAEs occurring in ≥15% of patients"). The columns are escalation monotherapy (N = 21), escalation combination (N = 15) and expansion combination (N = 41).

Fatigue | 6 (28.6) | 0 | 10 (66.7) | 0 | 9 (22.0) | 1 (2.4)

Injection-site pain | 0 | 0 | 0 | 0 | 13 (31.7) | 1 (2.4)

— Table 2B, same three cohorts. Each cohort has an "All grades" column followed by a "Grade ≥3" column. The table footer defines the rows as TEAEs.

Intratumoral administration of SAR441000 in combination with cemiplimab was generally well tolerated with antitumor activity in the locoregional disease setting.

— Abstract, Conclusions

What the paper's own numbers show

Method. Each incidence is 100 × (patients with the event) / (patients in the cohort), with the cohort sizes from the Abstract and Table 2 (21, 15, 41). For each of the Abstract's three figures, the script tries every incidence the paper reports for the same AE and cohort: all-grade and grade ≥3 rates, all-causality TEAEs (Table 2B) and treatment-related AEs (Supplementary Table S5). It also checks the figure against the cohort's ceiling for grade ≥3 TRAEs of any kind (Table 2A). Every number below is printed by recompute.py.txt.

Quantity Location Reported Recomputed from the paper's numbers
Fatigue, escalation monotherapy, labelled "grade ≥3 treatment-related" Abstract 28.6% equals all-grade TEAE 6/21 = 28.6% (Table 2B)
Grade ≥3 fatigue, escalation monotherapy Table 2B; Suppl. Table S5 0; 0 0/21 = 0.0% (all causes and treatment-related)
Any grade ≥3 TRAE, escalation monotherapy Table 2A; Results 0; "none were grade ≥3" 0/21 = 0.0%. Grade ≥3 TR fatigue of 28.6% would need 6.0 patients
Fatigue, escalation combination, labelled "grade ≥3 treatment-related" Abstract 66.7% equals all-grade TEAE 10/15 = 66.7% (Table 2B)
Grade ≥3 fatigue, escalation combination Table 2B; Suppl. Table S5 0; 0 0/15 = 0.0%
Any grade ≥3 TRAE, escalation combination Table 2A; Results 1 (6.7%) 1/15 = 6.7%. Grade ≥3 TR fatigue of 66.7% would need 10.0 patients
Treatment-related fatigue, any grade, escalation combination Results; Suppl. Table S5 n = 7; 46.7% 7/15 = 46.7%, so 66.7% is not a TRAE rate at any grade
Injection-site pain, expansion, labelled "grade ≥3 treatment-related" Abstract 31.7% equals all-grade TEAE 13/41 = 31.7% (Table 2B)
Grade ≥3 injection-site pain, expansion Table 2B; Suppl. Table S5 1 (2.4); 1 (2.4) 1/41 = 2.4%; the Abstract's figure is 13.0 times this
Treatment-related injection-site pain, any grade, expansion Suppl. Table S5 11 (26.8) 11/41 = 26.8%
Any grade ≥3 TRAE, expansion Table 2A; Results 6 (14.6%) 6/41 = 14.6%
Largest number of patients with any single grade ≥3 TRAE term, expansion Suppl. Table S5 7 terms with 1 (2.4) each 1/41 = 2.4%; no term is more common than any other
Ratio of Abstract figure to the cohort's any-grade ≥3 TRAE rate derived — monotherapy: 28.6% vs 0% (no finite ratio); combination: 66.7 / 6.7 = 10.0; expansion: 31.7 / 14.6 = 2.2

All three Abstract figures match the all-grade, all-causality TEAE rate exactly. None matches any grade ≥3 rate or any treatment-related rate the paper reports. In the two escalation cohorts the stated figures cannot be grade ≥3 TRAE rates at all. Even if every patient with a grade ≥3 TRAE of any kind had had grade ≥3 fatigue, the maximum would be 0/21 and 1/15.

Figure

The abstract's three "grade ≥3 treatment-related" figures next to the Table 2B cells they equal and the grade ≥3 rates from the same rows

Figure 1. The left panel shows the Abstract sentence and its three percentages (orange). Each arrow joins a percentage to the Table 2B row it reproduces exactly. In all three rows the match is the "All grades" cell (orange), the count of patients with the event at any grade and from any cause. The blue cells show the grade ≥3 rate recomputed from the adjacent "Grade ≥3" count in the same row: 0/21, 0/15 and 1/41. Underneath, the right panel gives the cohort-level ceiling from Table 2A (any grade ≥3 TRAE: 0/21, 1/15, 6/41) and the Results text on monotherapy and on treatment-related fatigue. Only patient counts and percentages printed in the paper, or computed from them by recompute.py.txt, are shown.

Dot plot comparing, on one percentage axis, the abstract's figures with the all-grade rate, the grade ≥3 rate and the any grade ≥3 TRAE ceiling for each cohort

Figure 2. The same comparison on one axis (percent of patients in each cohort, 0–100%). Orange dots are the Abstract's figures. Each sits inside an open ring marking the all-grade, all-causality rate from Table 2B. Blue diamonds are the grade ≥3 rates of the same AE (Table 2B), and open blue squares are the cohort's rate of grade ≥3 TRAEs of any kind (Table 2A). That second rate is an upper bound for any single grade ≥3 TRAE. In escalation monotherapy the diamond and the square coincide at 0%. In each cohort the Abstract's figure lies well above that upper bound.

Why it matters

Overall safety and tolerability are part of the trial's primary objective. The Abstract sentence quoted above is its only quantitative statement on safety. A reader of the Abstract alone would conclude that two-thirds of patients in escalation combination had severe treatment-related fatigue, and that nearly a third of expansion patients had severe treatment-related injection-site pain. The paper's tables say neither happened: no escalation patient had grade ≥3 fatigue, and 1 of 41 expansion patients had grade ≥3 injection-site pain. The sentence also misidentifies the "most common" grade ≥3 TRAE. Monotherapy had none. In escalation combination, the one patient with a grade ≥3 TRAE is described as having syncope. In expansion, Supplementary Table S5 lists seven grade ≥3 TRAE terms with one patient each, so no single term stands out.

The error runs against the paper's own conclusion. As printed, the Abstract's figures sit uneasily with "generally well tolerated"; the correct figures (grade ≥3 TRAEs of any kind in 0%, 6.7% and 14.6% of patients) support it. Abstract-level safety figures from first-in-human trials are often carried into reviews, meta-analyses of intratumoral immunotherapies and dose-selection discussions. A 10-fold or larger overstatement of severe toxicity could be passed on in those places.

The error does not affect the maximum administered dose (4,000 µg), the response counts, the pharmacokinetic and pharmacodynamic results, or the Discussion. The Discussion describes AE frequencies without the mislabelled percentages. It ends: "SAR441000 demonstrated a generally acceptable safety profile in both monotherapy and combination therapy cohorts, although a higher number of high-grade AEs were observed in the combination therapy cohort."

Explanations considered

A smaller inconsistency sits in the paper's supporting material. The Results text names the single grade ≥3 TRAE in escalation combination as syncope, citing Supplementary Table S5. That table lists syncope as 1 (6.7) at all grades and 0 at grade ≥3, and lists dizziness and peripheral neuropathy as 1 (6.7) each at grade ≥3. This does not change the main finding: Table 2A gives one patient with any grade ≥3 TRAE in that cohort either way.

Status

As of 2026-10-23:

Sources: doi.org/10.1158/1078-0432.CCR-24-1983 · PMC12163594 · Europe PMC record · Europe PMC supplementary files · Crossref works record · ClinicalTrials.gov NCT03871348

Suggested correction

The Abstract sentence could be replaced with figures that match Table 2 and Supplementary Table S5. One option:

Grade ≥3 treatment-related adverse events occurred in 0 of 21 (0%), 1 of 15 (6.7%) and 6 of 41 (14.6%) patients in escalation monotherapy, escalation combination and expansion combination, respectively. The most common any-grade adverse events were fatigue in escalation (monotherapy: 28.6%; combination: 66.7%) and injection-site pain (31.7%) in expansion.

The authors could also check which preferred term was recorded for the single grade ≥3 TRAE in escalation combination. The Results text names syncope, while Supplementary Table S5 lists dizziness and peripheral neuropathy.